• 28 October 2016

    GALWAY, Ireland, Oct. 28, 2016—4Tech Inc., a privately held clinical-stage company that is developingthe world’s first transcatheter device, TriCinch™, for repair of the Tricuspid heart valve, today announced that it has elected William (“Bill”) A. Hawkins as Chairman, effective immediately. Hawkins was previously Chairman and CEO of Medtronic from 2008—2011, which he joined in 2002 as Senior Vice President and President of Medtronic Vascular.

  • 27 October 2016

    Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies (mAbs) for pre-emptive and post-infection treatment of serious infectious diseases, today announced data from a prospective epidemiology study of the progression of Staphylococcus aureus airway colonization to pneumonia and the impact of antibiotics in mechanically ventilated intensive care unit (ICU) patients. The data demonstrate that S. aureus-active antibiotics did not significantly prevent or reduce heavy S. aureus colonization and did not halt progression to pneumonia. These results will be presented in a poster session at IDWeek 2016 in New Orleans on Friday, October 28.

  • 18 October 2016

     Additional analyses of data from COLLECT – a clinical study of InDex Pharmaceuticals Holding AB’s (publ) lead drug candidate cobitolimod for the treatment of moderate to severe active ulcerative colitis – was orally presented and met with great interest at the United European Gastroenterology Week (UEGW) 2016 in Vienna.

  • 12 October 2016

    Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, infectious diseases and autoimmune diseases, today announces the appointment of Paul Fry as Chief Financial Officer. 

  • 7 October 2016

    JenaValve Technology, Inc., a developer, manufacturer and marketer of differentiated heart-valve technology, and a company that is committed to making transcatheter aortic valve replacement (TAVR) available to the broadest spectrum of patients with aortic valve disease, today announced the appointment of veteran medical device executive Greg Mirigian as Vice President of Research and Development, effective immediately. Mirigian will be based in Irvine, Calif. at JenaValve’s corporate headquarters.